Fluctuations and downward pressures on GSK stock have periodically been tied to investor concerns regarding massive capital outlays for large-scale corporate acquisitions, such as its multi-billion-dollar buyout of Nuvalent. Market participants often weigh the heavy upfront premium costs, execution risks associated with integrating late-stage clinical pipelines, and looming patent cliffs against long-term growth strategies in oncology and specialty vaccines.